Related Experiment Video
Updated: Sep 28, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Hyperlipidemia management in diabetes: First line or supportive therapy?
1Department of Preventive Cardiology and Medicine, Eternal Heart Care Centre & Research Institute, Jaipur, India; Academic Research Development Unit, Rajasthan University of Health Sciences, Jaipur, India.
Managing high cholesterol and triglycerides is crucial for reducing heart disease in type 2 diabetes. Statins significantly lower risks, while other lipid-lowering treatments show varied results.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Background:
- Coronary heart disease (CHD) is a leading cause of death in type 2 diabetes.
- Therapeutic focus has shifted from glucose control to vasculoprotection.
- Hyperlipidemia management is key for CHD outcomes in diabetic patients.
Purpose of the Study:
- To review the impact of lipid management on CHD outcomes in type 2 diabetes.
- To highlight the role of LDL cholesterol and triglyceride reduction.
Main Methods:
- Literature search conducted until March 2022.
- Databases searched: PubMed, Google Scholar.
- Keywords: lipids, cholesterol, statins, triglycerides, fibrates, omega-3 PUFAs, LDL, diabetes, CHD.
Main Results:
- Moderate to high-intensity statins significantly reduce adverse CHD outcomes in diabetes.
- Triglyceride reduction with fenofibrate or omega-3 PUFAs has less robust evidence.
- A purified omega-3 PUFAs trial showed significant benefit.
Conclusions:
- Statins are recommended as first-line therapy for lipid lowering in diabetes.
- Comprehensive lifestyle changes and glucose control are essential adjuncts.
- Lipid management reduces CHD mortality and morbidity in diabetic individuals.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Angina IV: Management
Oral Hypoglycemic Agents: Biguanides and Glitazones
Coronary Artery Disease IV: Preventive Measures

